These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 28005346)
21. Systematic synthesis of novel phosphoglycolipid analogues as potential agonists of GPR55. Abe J; Guy AT; Ding F; Greimel P; Hirabayashi Y; Kamiguchi H; Ito Y Org Biomol Chem; 2020 Nov; 18(41):8467-8473. PubMed ID: 33063071 [TBL] [Abstract][Full Text] [Related]
22. The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. Kargl J; Balenga N; Parzmair GP; Brown AJ; Heinemann A; Waldhoer M J Biol Chem; 2012 Dec; 287(53):44234-48. PubMed ID: 23161546 [TBL] [Abstract][Full Text] [Related]
23. Identification of GPR55 as a lysophosphatidylinositol receptor. Oka S; Nakajima K; Yamashita A; Kishimoto S; Sugiura T Biochem Biophys Res Commun; 2007 Nov; 362(4):928-34. PubMed ID: 17765871 [TBL] [Abstract][Full Text] [Related]
24. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion. Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453 [TBL] [Abstract][Full Text] [Related]
25. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Ford LA; Roelofs AJ; Anavi-Goffer S; Mowat L; Simpson DG; Irving AJ; Rogers MJ; Rajnicek AM; Ross RA Br J Pharmacol; 2010 Jun; 160(3):762-71. PubMed ID: 20590578 [TBL] [Abstract][Full Text] [Related]
26. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells. AlSuleimani YM; Hiley CR Br J Pharmacol; 2015 Jun; 172(12):3043-57. PubMed ID: 25652040 [TBL] [Abstract][Full Text] [Related]
27. GPR55 ligands promote receptor coupling to multiple signalling pathways. Henstridge CM; Balenga NA; Schröder R; Kargl JK; Platzer W; Martini L; Arthur S; Penman J; Whistler JL; Kostenis E; Waldhoer M; Irving AJ Br J Pharmacol; 2010 Jun; 160(3):604-14. PubMed ID: 20136841 [TBL] [Abstract][Full Text] [Related]
28. Lysophosphatidylinositol Induced Morphological Changes and Stress Fiber Formation through the GPR55-RhoA-ROCK Pathway. Nakajima K; Oka S; Tanikawa T; Nemoto-Sasaki Y; Matsumoto N; Ishiguro H; Arata Y; Sugiura T; Yamashita A Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142844 [TBL] [Abstract][Full Text] [Related]
29. The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling. Calvillo-Robledo A; Cervantes-Villagrana RD; Morales P; Marichal-Cancino BA Life Sci; 2022 Jul; 301():120596. PubMed ID: 35500681 [TBL] [Abstract][Full Text] [Related]
30. Lysophosphatidylinositols, from Cell Membrane Constituents to GPR55 Ligands. Alhouayek M; Masquelier J; Muccioli GG Trends Pharmacol Sci; 2018 Jun; 39(6):586-604. PubMed ID: 29588059 [TBL] [Abstract][Full Text] [Related]
31. Generation of lysophosphatidylinositol by DDHD domain containing 1 (DDHD1): Possible involvement of phospholipase D/phosphatidic acid in the activation of DDHD1. Yamashita A; Kumazawa T; Koga H; Suzuki N; Oka S; Sugiura T Biochim Biophys Acta; 2010 Jul; 1801(7):711-20. PubMed ID: 20359546 [TBL] [Abstract][Full Text] [Related]
32. Advances Towards The Discovery of GPR55 Ligands. Morales P; Jagerovic N Curr Med Chem; 2016; 23(20):2087-100. PubMed ID: 27109575 [TBL] [Abstract][Full Text] [Related]
33. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Piñeiro R; Maffucci T; Falasca M Oncogene; 2011 Jan; 30(2):142-52. PubMed ID: 20838378 [TBL] [Abstract][Full Text] [Related]
34. Free fatty acid receptors: structural models and elucidation of ligand binding interactions. Tikhonova IG; Poerio E BMC Struct Biol; 2015 Sep; 15():16. PubMed ID: 26346819 [TBL] [Abstract][Full Text] [Related]
35. Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. Kotsikorou E; Lynch DL; Abood ME; Reggio PH Chem Phys Lipids; 2011 Feb; 164(2):131-43. PubMed ID: 21185816 [TBL] [Abstract][Full Text] [Related]
36. Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors. Shang Y; Yeatman HR; Provasi D; Alt A; Christopoulos A; Canals M; Filizola M ACS Chem Biol; 2016 May; 11(5):1220-9. PubMed ID: 26841170 [TBL] [Abstract][Full Text] [Related]
37. Plasticity of the ligand binding pocket in the bitter taste receptor T2R7. Liu K; Jaggupilli A; Premnath D; Chelikani P Biochim Biophys Acta Biomembr; 2018 May; 1860(5):991-999. PubMed ID: 29355483 [TBL] [Abstract][Full Text] [Related]
38. Involvement of Trp-284, Val-296, and Val-297 of the human delta-opioid receptor in binding of delta-selective ligands. Valiquette M; Vu HK; Yue SY; Wahlestedt C; Walker P J Biol Chem; 1996 Aug; 271(31):18789-96. PubMed ID: 8702536 [TBL] [Abstract][Full Text] [Related]
39. GPR55-mediated effects on brain microvascular endothelial cells and the blood-brain barrier. Leo LM; Familusi B; Hoang M; Smith R; Lindenau K; Sporici KT; Brailoiu E; Abood ME; Brailoiu GC Neuroscience; 2019 Aug; 414():88-98. PubMed ID: 31279825 [TBL] [Abstract][Full Text] [Related]
40. Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors. Imbernon M; Whyte L; Diaz-Arteaga A; Russell WR; Moreno NR; Vazquez MJ; Gonzalez CR; Díaz-Ruiz A; Lopez M; Malagón MM; Ross RA; Dieguez C; Nogueiras R Mol Cell Endocrinol; 2014 Mar; 383(1-2):159-69. PubMed ID: 24378736 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]